WO1998016101A1 - Reagent system and kit for detecting hiv infected cells - Google Patents
Reagent system and kit for detecting hiv infected cells Download PDFInfo
- Publication number
- WO1998016101A1 WO1998016101A1 PCT/US1997/018649 US9718649W WO9816101A1 WO 1998016101 A1 WO1998016101 A1 WO 1998016101A1 US 9718649 W US9718649 W US 9718649W WO 9816101 A1 WO9816101 A1 WO 9816101A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- cell
- antigen
- mixture
- cells
- Prior art date
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 87
- 238000012360 testing method Methods 0.000 claims abstract description 115
- 238000000034 method Methods 0.000 claims abstract description 106
- 239000000427 antigen Substances 0.000 claims abstract description 104
- 108091007433 antigens Proteins 0.000 claims abstract description 104
- 102000036639 antigens Human genes 0.000 claims abstract description 104
- 230000005291 magnetic effect Effects 0.000 claims abstract description 81
- 210000004369 blood Anatomy 0.000 claims abstract description 71
- 239000008280 blood Substances 0.000 claims abstract description 71
- 239000006249 magnetic particle Substances 0.000 claims abstract description 61
- 241000700605 Viruses Species 0.000 claims abstract description 50
- 238000001514 detection method Methods 0.000 claims abstract description 19
- 238000000926 separation method Methods 0.000 claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims description 244
- 239000000203 mixture Substances 0.000 claims description 94
- 230000027455 binding Effects 0.000 claims description 82
- 230000003612 virological effect Effects 0.000 claims description 40
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 33
- 238000006243 chemical reaction Methods 0.000 claims description 32
- 239000002245 particle Substances 0.000 claims description 30
- 230000005298 paramagnetic effect Effects 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 23
- 239000011324 bead Substances 0.000 claims description 21
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- 238000000684 flow cytometry Methods 0.000 claims description 15
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 14
- 208000036142 Viral infection Diseases 0.000 claims description 12
- 230000009385 viral infection Effects 0.000 claims description 12
- 244000005700 microbiome Species 0.000 claims description 10
- 108020003175 receptors Proteins 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 210000003811 finger Anatomy 0.000 claims description 5
- 239000004816 latex Substances 0.000 claims description 5
- 229920000126 latex Polymers 0.000 claims description 5
- 210000003813 thumb Anatomy 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 102000018265 Virus Receptors Human genes 0.000 claims 4
- 108010066342 Virus Receptors Proteins 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 101710160107 Outer membrane protein A Proteins 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 230000002452 interceptive effect Effects 0.000 claims 2
- 239000011369 resultant mixture Substances 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 41
- 238000007885 magnetic separation Methods 0.000 abstract description 28
- 238000002156 mixing Methods 0.000 abstract description 9
- 238000000576 coating method Methods 0.000 abstract description 5
- 239000011248 coating agent Substances 0.000 abstract description 4
- 238000012546 transfer Methods 0.000 abstract description 3
- 208000031886 HIV Infections Diseases 0.000 description 47
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 36
- 239000004005 microsphere Substances 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 238000011534 incubation Methods 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 229920002799 BoPET Polymers 0.000 description 11
- 239000005041 Mylar™ Substances 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 10
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 10
- 208000037357 HIV infectious disease Diseases 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 241001529936 Murinae Species 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 7
- -1 etc. Chemical compound 0.000 description 7
- 239000011325 microbead Substances 0.000 description 7
- 102100034349 Integrase Human genes 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000006399 behavior Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 4
- 101710205625 Capsid protein p24 Proteins 0.000 description 4
- 101710121417 Envelope glycoprotein Proteins 0.000 description 4
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 4
- 101710177166 Phosphoprotein Proteins 0.000 description 4
- 101710149279 Small delta antigen Proteins 0.000 description 4
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 4
- 239000006148 magnetic separator Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 3
- 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 2
- 108010041397 CD4 Antigens Proteins 0.000 description 2
- 108010061299 CXCR4 Receptors Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 2
- 108070000030 Viral receptors Proteins 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000007878 drug screening assay Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005294 ferromagnetic effect Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000004884 risky behavior Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000013077 target material Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 108010017088 CCR5 Receptors Proteins 0.000 description 1
- 102000004274 CCR5 Receptors Human genes 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000777599 Homo sapiens C-C chemokine receptor type 2 Proteins 0.000 description 1
- 101000738584 Homo sapiens C-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 241000500891 Insecta Species 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101001037768 Plasmodium berghei 58 kDa phosphoprotein Proteins 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 229960002089 ferrous chloride Drugs 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- 229940096010 iron polysaccharide Drugs 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011553 magnetic fluid Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000017960 syncytium formation Effects 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000024058 virion binding Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
Definitions
- This invention relates to blood collection and diagnostics. More particularly, the invention relates to blood collection and diagnostics utilizing techniques such as magnetic separation and photodetection.
- the present invention also relates to methods and an apparatus for detecting the presence of antigens displayed on the surface of cells. More preferably, the present invention relates to the detection of cells infected by human immunodeficiency virus (HIV) and related viruses.
- HIV-infected cells can be detected and separated from uninfected cells. In a preferred embodiment, separation is achieved by a magnetic field. By coating the infected cells with magnetic particles, transfer of the cells to a precise location is facilitated.
- a novel aspect of the present invention is a cartridge antigen test which allows for the collection and mixing of blood with reagents in one package, which can be viewed on a fluorescent microscope.
- the present invention relates to methods and materials useful in the early diagnosis of HIV infections. More particularly, in one embodiment, the invention provides compositions and methods for utilizing commercially available high affinity and highly specific magnetically coupled monoclonal antibodies to an envelope surface glycoprotein of HIV- 1, such as gpl20, along, with commercially available FITC conjugated polyclonal antibodies to the envelope glycoprotein, e.g., gp 120, for the purpose of isolating and fluorescing HIV-1 infected peripheral blood lymphocytes in whole blood.
- the invention can be used with another invention known as the Mehica GP120 Dectector, an automated fluorescent microscope system that incubates and reads cartridge antigen tests.
- Infection of a T cell with HIV-1 follows from interaction between an epitope borne by HIV-1 and the CD4 receptor which is located on the T cell surface.
- the epitope on HIV-1 is borne by the envelope glycoprotein gpl20 (molecular weight 120 kilodaltons).
- the glycoprotein GP 120 is structurally exposed on the outside of the
- the gp 120 binds to the CD4 antigens which exist on the cell surface of the helper T cells, etc., and in addition to providing the fusion point between the virus and the T helper cell, gpl20 possesses activity which results in syncytium formation, the mechanism of cell to cell infection with HIV-1, as described in detail in U.S. Patent No. 4,725,699.
- HIV-1 Human Immunodeficiency Virus Type 1
- HIV antibody tests have their limitations. Usually antibodies to HIV appear within 3-6 months and as early as 6-8 weeks, but silent infections have been documented in which seroconversion has occurred as late as 3 years from the moment of exposure. Therefore, because an infected person does not develop antibodies immediately, a negative test result cannot rule out HIV infection. It has been shown that the majority (90%) of people first testing positive for
- HIV will develop AIDS within one year. This strongly suggests that the average person identifying HIV infection has been positive for an average of 8-9 years, in view of the fact that the average interval between infection an AIDS is 9-10 years.
- a method for determining the concentration of substances in biological fluids wherein magnetically responsive , permeable, solid, water insoluble, micro particles are employed is disclosed in U.S. Pat. No. 4,115,534.
- Functional magnetic particles formed by dissolving a mucopolysaccharide such as chitosan in acidified aqueous solution containing a mixture of ferrous chloride and ferric chloride is disclosed in U.S. Pat. No. 4,285,819.
- the micro spheres may be employed to remove dissolved ions from waste aqueous streams by formation of chelates.
- U.S. Pat. No. 3,933,997 describes a solid phase radio immunoassay for digoxin where anti-digoxin antibodies are coupled to magnetically responsive particles.
- Small magnetic particles coated with an antibody layer are used in U.S. Pat. No. 3,970,518 to provide large and widely distributed surface area for sorting out and separating select organisms and cells from populations thereof.
- U.S. Pat. No. 4,018,886 discloses small magnetic particles used to provide large and widely distributed surface area for separating a select protein from a solution to enable detection thereof. The particles are coated with a protein that will interact specifically with the select protein.
- compositions comprising stable, water insoluble coatings on substrates to which biologically active proteins can be covalently coupled so that the resulting product has the biological properties of the protein and the mechanical properties of the substrate, for example, magnetic properties of a metal support.
- a diagnostic method employing a mixture of normally separable protein-coated particles is discussed in U.S. Pat. No. 4,1 15,535.
- Micro spheres of acrolein homopolymers and copolymer with hydrophilic comonomers such as methacrylic acid and/or hyroxyethylmethacrylate are discussed in U.S. Pat. No. 4,413,070.
- U.S. Pat. No. 4,452,774 discloses magnetic iron-dextran micro spheres which can be covalently bonded to antibodies, enzymes and other biological molecules and used to label and separate cells and other biological particles and molecules by means of a magnetic field.
- Coated magnetizable micro particles, reversible suspensions thereof, and processes relating thereto are disclosed in U.S. Pat. No. 4,454,234.
- a method of separating cationic from anionic beads in mixed resin beds employing a ferromagnetic material intricately incorporated with each of the ionic beads is described in U.S. Pat. No. 4,523,996.
- a magnetic separation method utilizing a colloid of magnetic particles is discussed in U.S. Pat. No. 4,526,681.
- U.K. Patent Application GB No. 2, 152,664A discloses magnetic assay reagents.
- Magnetic protein A micro spheres and their use in a method for cell separation are disclosed by Widder,et al. (1979) Clin. Immunol, and Immunopath. 14:395-400.
- U.S. Patent No. 5,279,936 is a method directed to the separation of a component of interest from other components of a mixture by causing the binding of the component of interest to magnetic particles.
- the method comprises layering a first liquid medium containing cells and other components with a second medium which is of a different density than and/or different viscosity than the first liquid medium.
- the cells are bound to paramagnetic particles.
- the layered first liquid medium and the second liquid medium are subjected to a magnetic field gradient to cause the cell particles to migrate into the second medium.
- the purpose of isolating the cells in the second liquid medium is to then by a further embodiment to separate the cells from the second liquid medium.
- U.S. Patent No. 4,935,147 is a method that specifically targets the application of magnetic separation in the assay of organic and inorganic biochemical analytes, particularly those analytes of interest in the analysis of body fluids.
- the method of the mentioned patent provides a way of separating non-magnetic particles from a medium by virtue of the chemically controlled non-specific reversible binding of such particles to magnetic particles. Because of the small size of the magnetic particles, it also provides for a very rapid binding of a substance to be separated. By then aggregating the particles there is provided a much more rapid and complete magnetic separation than has been achieved by previous methods.
- this technique of magnetic separation does not apply because of the fact the antigen of interest is bound to cells, and therefore not in solution or in need of agglutinaton for separation.
- the current invention merely requires the adherence of the many magnetic particles to an infected cell surface to magnetically pull the entire cell of interest to a predetermined point in the reaction vessel for viewing.
- the prior art collected blood for testing in multiple steps. The first step was to collect the blood into a suitable container from a puncture wound in the skin of a finger or by venipuncture. Then the blood would have to be placed into a container suitable for transporting or mixing with test reagents. Then reagents would have to be added in a multiple step fashion, interrupted by wash steps. The problem with this approach is multiple steps which are time consuming and require training. In the collection of blood, the prior art is still dealing with the lance and test tube methods.
- the aforementioned U.S. patent 4,777,964 to David Briggs, Kent A. Leger, Brenda Briggs (10/18/88) provides a system for whomever wishes to ascertain whether or not he is carrying the AIDS virus to perform a blood sampling and to forward the sample to a lab for the further testing
- the kit contains a lance and a tube for collecting the sample and requires the user to seal the tube at the ends with putty.
- This device and kit is only a means for collecting blood and keeping the sample intact for mailing to a laboratory for further testing. No tests are performed using the appliances provided.
- the sample must be transferred to a testing vessel and mixed with the appropriate testing medium.
- the magnetic separator includes a non-magnetic container having a peripheral wall with an internal surface area for receiving the test medium, and magnetic means for generating a magnetic field gradient within the container in which tested material is contained in reaction vessels such as test tubes.
- reaction vessels such as test tubes.
- U.S. patent 5,238,810 to Koichi Fujiwara, Juichi Noda, Hiroko Misutani, Hiromichi Mizutani (08/23/93) provides for such a process; however, as with other magnetic separation methods, this method involves multiple apparatus and steps just to collect and prepare the blood samples for testing.
- This method also focuses on using one reagent for its test, rather than on a double reagent mixture. It provides for various vessel configurations for performing the reaction, but does not include or contemplate a vessel that has served as reagent storage, blood collection, mixture, incubation and viewing device in one.
- the present invention relates to a variety of assays for detecting and/or separating, e.g., pbls, T-cells, immortalized cell lines, macrophages, artificial liposomes, etc., utilizing magnetic separation technology.
- it relates to obtaining a blood sample and mixing it with testing reagents in one step, and in one disposable vessel.
- the vessel can be incubated and the related results of reaction between the reagents and the blood sample can be viewed and read in the vessel by a fluorescent microscope without additional processing for quick and accurate testing.
- the present invention is directed to blood collection and magnetic separation apparatus and methods in which antibody-coupled magnetic particles and antibody- conjugated flourochromes are used to isolate substances of interest from a nonmagnetic test medium by means of high gradient magnetic separation and identification by application of focused light.
- An aspect of the present invention relies upon a unique reaction vessel that serves the multiplicity of purposes as stated above.
- the prior methods of magnetic separation differ in various ways, e.g., because of the incompatibility of reaction vessel configuration with blood sample collection and single-step testing.
- most magnetic separation devices do not provide for viewing any further reaction within the vessel.
- the current invention provides a self-contained micro-baggy of reagents that is punctured and permitted to mix with the sample of blood at the same time the sample is being collected.
- the chamber in which the blood is collected, and in which the reagents are mixed with the blood is also the same chamber or vessel used for incubating the reaction mixture, and further, is the chamber in which magnetic separation of the infected cells, if present, is performed.
- the Cartridge Antigen Test is a device that permits blood collection, reagent mixing with blood, incubation of the mixture, magnetic separation, and viewing of the test results.
- the device consists of a well slide with micro-lances, a micro-baggy full of reagents, a mylar cover strip, and a bar code for identification purposes.
- the present invention also relates to a fluorometric immunoassay in which a pair of manufactured non-competitive antibodies to a surface antigen, such as gpl20, are utilized.
- a surface antigen such as gpl20
- One antibody is coupled to paramagnetic particles, while the second in conjugate with FITC.
- the present invention takes advantage of the technology of immunomagnetic separation developed over the past 15 years to enrich or separate out of a mixture of cells, specific cellular components based on their specific immunological markers. See, e.g., U.S. Patents 4,777,145; 4,731,337; 5,186,827; 5,238,810; 5,279,936; 5,411,863; and 4,935, 147.
- Fig. 1 is a frontal view of a collection/processing cartridge according to the present invention.
- Fig. 2 is a side view of the collection/processing cartridge illustrating a well, micro-lances, a micro-baggy and a mylar cover.
- Fig. 3 is an enlarged view of one of the micro-lances shown in Fig. 2.
- Fig. 4A-4C are side views illustrating the collection of a blood sample from a test subject.
- Fig. 5A-5E are side views of the well and illustrating an immunochemical reaction between blood and a two reagent system including incubation, application of a magnetic gradient, and the application of a focused light source on the reagent and blood mixture.
- Fig. 6A-6C are top and side views respectively, of the cartridge and well illustrating incubation, the application of a magnetic gradient and a focused light source, and the observation of the reaction through a lens.
- Multi-purpose cartridge and fully automated incubator, magnetic separator and imaging system permit operation by non-medically trained personnel; 3. Appearance of cell-bound gpl20 parallels appearance of viral genetic material, enabling invention to detect HIV presence in same time period as "Gold Standard” PCR at a small fraction of the cost; 4. Functional design of the blood collection/ immunochemistry/ magnetic separation/ imaging cartridge permit complete, self contained, disposable unit that is much easier to handle than "gold standard” PCR test for viral genetic material; 5. Entire test procedure requires minutes to turn around compared with weeks for PCR; 6. Cost per test will be in tens of dollars rather than hundreds. Still further objects and advantages will become apparent from a consideration of the ensuing description and accompanying drawings.
- a sample of several drops of whole blood is diluted with murine anti-gpl20 monoclonal antibodies coupled to paramagnetic microspheres approximately 0.5 cc Phosphate Buffered Saline (PBS).
- PBS Phosphate Buffered Saline
- To the diluled sample is added the Murine anti-gpl20 monoclonal antibodies coupled to paramagnetic microspheres, and the Fluorescein conjugated anti-gpl20 polyclonal antibodies IgG.
- the sample of diluted whole blood are a small number of HIV infected peripheral blood lymphocytes, bearing CD-4, also bearing numerous exposed gpl20 antigens.
- both antibodies are non-competitively bound to each and every gp 120 antigen. This renders each HIV infected peripheral blood lymphocytes coated with both the murine anti-gpl20 monoclonal antibodies coupled to paramagnetic micro spheres and the Fluorescein conjugated anti-gpl20 polyclonal antibodies IgG. The uninfected peripheral blood lymphocytes remain uncoated by either of the antibodies.
- a vessel containing the mixture of incubated blood and reagents can be exposed to a strong magnetic gradient at a predetermined point on the outer surface of the reaction vessel.
- the magnetic field causes the migration of all HIV infected peripheral blood lymphocytes to the inner surface of the reaction vessel at the maximum point of concentration of the magnetic gradient, thus separating the HIV infected peripheral blood lymphocytes from the uninfected peripheral blood lymphocytes in the diluted whole blood sample.
- the magnetic separation takes approximately 20 seconds.
- the predetermined point of maximum magnetic concentration is illuminated by a suitable focused light source at 488 nm wavelength, causing all HIV infected peripheral blood lymphocytes, now aggregated at the at a predetermined point to glow at between 520-540 nm fluorescent light.
- Fluorescein conjugated anti-gpl20 polyclonal antibodies IgG unbound to HIV infected peripheral blood lymphocytes in the sample of diluted blood, the volume is sufficient and dilution of Fluorescein conjugated anti-gpl20 polyclonal antibodies IgG adequate to provide only a low intensity diffuse background fluorescence as compared to the high intensity of cell bound Fluorescein conjugated anti-gpl20 polyclonal antibodies IgG visible by fluorescence microscopy on the infected cells adhering to the inner surface of the reaction vessel wall.
- the excess of magnetic particles unbound immunologically to cell surfaces will travel at a much greater velocity to the inner surface of the vessel wall, assuring that before any cell coated with magnetic particles arrive at the vessel wall, there will have formed a dark coating of unbound Murine anti-gpl20 monoclonal antibodies coupled to paramagnetic micro spheres, against which the infected cells will adhere, also providing a nice contrast for the high density of glowing HIV infected peripheral blood lymphocytes.
- Reagents can be obtained commerically, e.g., Immunodiagnostics, Inc., Murine
- Anti-gp 120 HIV-1 mAb Coupled to Paramagmetic Microspheres Mnoclonal antibodies of mouse origin can be obtained commerically which are highly specific with high affinity to the gpl20 HIV-1 glycoprotein. They are cross-reactive and cross neutralizing antibodies, which are covalently bonded to Paramagnetic Microspheres. Their coupling ratio is approximately 2.5 micrograms of protein per mg of magnetic microspheres. Specificity testing demonstrates that the Magnetic Murine anti-gp 120 mAb binds recombinant gpl20 (MN, IIIB) peroxidase conjugate as determined by ELISA. The biological activity is defined as the binding of these antibodies to CD-4 bearing, HIV-1 infected cells and HIV-1 infected human peripheral blood lymphocytes. Fluorescein Rabbit Anti-gp 120 HIV- 1 IIIB pAb IgG (e.g., Immunodiagnostics, Inc.)
- Fluorescein conjugated anti-gp 120 (HIV-1 IIIB) pAg IgG can be highly purified (95% pure) polyclonal IgG before use for FITC conjugation. The conjugate can then be further purified by gel exclusion chromatography. The specificity of this fluorescein conjugated pAb IgG can be defined by its binding to native and recombinant HIV-1 gpl20 in Dot Blot assays and by its staining of cell surfaces in direct immunofluorescence assays. This reagent can be used for direct immunofluorescence assays.
- This reagent can be used for direct immuno fluorescent staining of cells in the 1 :50 dilution range, while Dot blot assays with purified gpl20 may be performed at a minimum dilution of 1 : 100.
- Both monoclonal and polyclonal antibodies can be obtained (e.g., see above) which bind to the V3 loop of the HIV-1 envelope glycoprotein gpl20 but which are not competitive, i.e., they attach to different regions of the V3 loop of gpl20. This factor permits them to be used simultaneously for their specific and different purposes.
- Cell- bound antigen-based test closes the window period created by having to rely on the host immune system to produce antibodies against HIV-1 antigens to around four days; Appearance of cell-bound gpl20 parallels appearance of viral genetic material, enabling invention to detect HIV presence in same time period as "gold standard” PCR at a small fraction of the cost; Entire test procedure requires minutes to turn around compared with weeks for PCR; Increased accuracy and low cost allow it to act as both screening and confirmatory test;
- This test can also be utilized in an automated format, utilizing a multi-purpose cartridge and fully automated incubator magnetic separator and imaging system, permitting operation by non-medically trained personnel; The test can be contained in a blood collection cartridge to permit complete, self contained, disposable unit that is much easier to handle than "gold standard” PCR test for viral genetic material.
- the method can be used to test for other viral infections by varying the antibodies combinations, other fluorochromes to could be utilized, the method can be used test for water contamination, the method can be used to separate and identify cancer cells.
- the present invention relates to an assay for determining the presence of a desired antibody or other binding partner in a test sample.
- the desired antibody is an antibody generated against an antigen coded for by a virus, e.g., HIV-1, HIV-2, HTLV, HTLV EBV, CMV, SIV, etc.
- the antibody is a neutralizing antibody or an antibody able to interfere with infection of a cell by the virus.
- the presence of the antibody in the test sample is determined by its ability to interfere with infection of a target cell by a virus.
- a target cell is contacted with a virus capable of infecting the cell.
- the step of contacting can be achieved, e.g., by combining the target cell and virus in a receptacle, such as a test tube, a slide well, a tissue culture flask, etc.
- a receptacle such as a test tube, a slide well, a tissue culture flask, etc.
- the step of contacting is performed in a liquid phase; however, a solid phase can also be used.
- a target cell which is useful in the present invention is one which is susceptible or receptive to being infected by a desired virus, e.g., HIV-1.
- a desired virus e.g., HIV-1.
- Various cells can be used, including, primary cells such as CD4(+)T cells or splenic cells, T cell lines, lymphoblastoid cell lines, H9, C8166, Molt, Molt-4, CEM, Jurkat, preferably, CEM74. See, e.g., Virology, 236:208-212, 1997.
- a target cell can be contacted with the virus under conditions effective to achieve infection of the cell with the virus.
- factors e.g., cofactors, protein, cytokines, ions
- environments, ingredients, etc. useful for the virus to infect the cell, e.g., to attach to the cell, enter the cell, and pirate the cell's machinery for its own benefit.
- These conditions can be routinely determined, e.g., including optimizing pH, temperature, salts, buffers, virus concentrations, cell numbers, etc.
- the effective conditions also can mean a media or other liquid environment in which invasion of the cell by a virus is accomplished.
- a media can include growth factors and other compounds which facilitate the virus's entry into a cell.
- Any suitable buffer system can be used, including, e.g., PBS, Tris, sodium citrate, etc., borate, etc.
- the combination of the target cell and virus can be referred to as a mixture.
- the target cell is contacted with the virus, a mixture is formed.
- the contacting is accomplished in a suitable environment for infection and expression of an antigen associated with viral infection, e.g., gpl20, gp41, etc.
- a feature of the invention is detection of the viral antigen on the cell surface and detection of agents which interfere with its expression. Detection of the antigen can be achieved directly or indirectly.
- one or more receptors for a viral antigen e.g., CD4, CKR5, CC-CKR5, CCR5, CKR2, CKR2B, CKR3, CKR4, CXCR4, CCR2, fusin, etc
- CKR5, CC-CKR5, CCR5, CKR2, CKR2B, CKR3, CKR4, CXCR4, CCR2, fusin, etc can be coupled to a surface (e.g., a magnetic particle, bead, or miscrosphere) and then used to capture cells expressing the viral antigen.
- a surface e.g., a magnetic particle, bead, or miscrosphere
- an indirect means of capture is used.
- a first binding partner specific for an antigen coded for by the virus which is expressed on the cell upon viral infection, is added to the mixture.
- the term "specific” has its normal art-recognized meaning, e.g., it is has a higher affinity for the viral antigen than other antigens present in the mixture.
- the binding partner can be added at the same time as the virus, or, after the virus has been added to the mixture.
- the conditions used are those which permit (e.g., "effective") for the binding partner to attach to the viral antigen as it is expressed on the cell surface, or otherwise displayed by the cell.
- the binding partner can be any agent which recognizes the viral antigen, e.g., aptamers, PNA structures, peptides, small molecules, antibodies (monoclonal, polyclonal, chimeric, single-chain, divalent, disulfide-stabilized Fv fragments, etc.), receptors for a viral antigen (e.g., CKR5, CD4), etc.
- Methods for making antibodies are well-known in the art
- Antibodies can also be obtained from commercial sources, e.g., Immunodiagnostics, Waltham, MA.
- the cell can be captured directly if the binding partner is attached to a substrate, e.g., a magnetic particle, or, it can be captured by using a second binding partner which is able to specifically recognize the first binding partner, i.e., specifically bind to among a mixture of molecules, antigens, agents, antibodies, etc.
- a substrate e.g., a magnetic particle
- the second binding partner is preferably attached to a substrate, e.g., a latex bead, a glass slide, a microwell, a magnetic bead or particle, etc. Attachment of the binding partner to the substrate can be accomplished according to conventional methods. See, e.g., USP 5,543,289; Luk and Lindberg, J. Immunol.
- a viral receptor as the primary binding partner utilized to capture the target material, e.g., a cell infected with a virus.
- a receptor for HIV is a preferred reagent for several reasons. It is a universal primary binding site for most subtypes, strains, and clades of the HIV virus and is also on most HIV receptive cells. Because an already HTV-infected cell expresses the gpl20 envelope protein diffusely distributed over its entire membrane surface, and because purified (recombinant or from natural sources) CD4 has a high specificity and affinity for gpl20 , it useful to capture material containing gpl20. For purification, see, e.g., USP 5,603,933; Deen et al., Nature,
- CD4 can be used indirectly to capture target material, in accordance with the methods described above and below.
- CD4 can be conjugated to a moiety, e.g., FITC, and employed to capture, e.g., HIV-infected cells in mixture which contains both infected and uninfected cells.
- Magnetic particles containing anti-FITC antibody can be used in turn to label the cells coated with the CD4-FITC.
- the mixture can then be passed through a separator column causing positive selection of all the HIV-infected cells in the mixture, while depleting the uninfected cells. After depleting uninfected cells from the mixture, a separation column can be removed from the magnetic filed and the HIV-infected cells eluted with
- the FITC-conjugated CD4 labeled cells can then be fixed and counted by standard flow cytometry. Cells infected with other viruses can be selected analogously.
- the second binding partner is attached to a magnetic particle (bead, microsphere, etc.), e.g., as described in USP 5,411,863; USP
- a magnetic particle can be comprised of any effective type, e.g., ferromagnetic, supermagnetic, paramagnetic, and superparamagnetic.
- a preferred particle is comprised of iron oxide and polysaccharide.
- a preferred magnetic bead has a diameter which is less than the diameter of the cell which is to be captured, e.g., about 1-300 nm, about 5-200 nm, about 10-150 nm, preferably, about 20-150 nm, more preferably, about 50-120 nm.
- the magnetic beads are of a sufficient size that they can form a coating around the cell, e.g., having more than one bead attached to the cell, such as about 10 beads, about 100 beads, about 1000, or about 100-1000 etc. These beads be manufactured or commercially obtained e.g., Milteni Biotech, Germany.
- the second binding partner is selected for its ability to specifically bind to the first binding partner, i.e., recognize and attach to it with a higher affinity than other components in the cell mixture.
- the second binding partner can be of any material, e.g., those described for the first binding partner.
- the first binding partner comprises a moiety which is recognized specifically the second binding particle.
- the moiety can be attached conventionally to the binding partner.
- a moiety can be, for instance, a hapten or detectable label, such as a fluorochrome, e.g., FITC, TRITC, R-phycoerythrin, Quantum Red, or Cy3, gold, ferritin, biotin, avidin, streptavidin, green fluorescent protein GFP (Chalfie et al., 1994, Science, 263:802; Cheng et al., 1996, Nature Biotechnology, 14:606; Levy et al., 1996, Nature
- a fluorochrome e.g., FITC, TRITC, R-phycoerythrin, Quantum Red, or Cy3, gold, ferritin, biotin, avidin, streptavidin, green fluorescent protein GFP
- a first binding partner can be an anti-gp 120 antibody conjugated to FITC and the second binding partner can be an anti-FITC antibody.
- the first binding partner can be a receptor for a viral antigen expressed on the cell surface upon viral infection (e.g., CD4, CKR5, fusin, etc).
- a second binding partner can be selected which is specific for the viral receptor.
- Such binding partner can be an antibody which recognizes an epitope, etc., on the receptor.
- the receptor can also comprise a moiety, as mentioned above, and the second binding partner can be an agent which recognizes the moiety, e.g., where the first binding partner is a receptor conjugated to FITC, the second binding partner can be an anti- FITC antibody preferably coupled to one or more paramagnetic microspheres.
- a second binding partner can be added at the same time as when the virus is contacted with the cell, or it can be added later, e.g., after cell contact, after addition of the first binding partner.
- a virus or mixture of viruses are added to the cells and then incubated for a sufficient amount of time for the virus to infect the cell and for the cell to display evidence of such infection (e.g., surface expression of gpl20 or gp41).
- the first and second binding partner can then be added in subsequent and sequential steps. After each addition, optionally, an incubation period is utilized providing adequate time for the binding partner to attach to its substrate. Such times can be routinely determined.
- a cell-antigen- first binding partner-second binding partner combination is formed.
- the antigen-first binding partner-second binding partner combination can be referred to as a complex when at least these three components are joined together and attached to a cell.
- the complex included a magnetic particle, e.g., when the second binding particle is attached to it.
- separation can be achieved conventionally by a magnetic field. See, e.g., USP Nos. 5,541,072; 5,543,289; 5,238,810; 5,196,827; 4,731,337, e.g., by positive selection.
- a chamber having an inlet and outlet is filled via the inlet with a sample.
- the sample contains, e.g., the cells (such as HIV-infected cells) coated with paramagnetic microspheres.
- a material which is capable of expressing a magnetic field surrounds the filled chamber.
- a magnetic field is applied to the column, retaining the cells coated with the paramagnetic beads, and allowing the uncoated cells to flow out through the outlet of the chamber.
- the infected, coated cells can be eluted by releasing the magnetic field.
- the chamber can comprise any material or matrix, including materials or matriices capable of expressing a magnetic field. Such technology is conventional.
- USP 5,411,863 describes an apparatus, system, and particles which can be used in the present invention.
- a related aspect of the present invention is the identification of agents which interfere, modulate, prevent, or enhance, viral infection of a cell.
- agents can be antibodies, small molecules, aptamers, ribozymes (hammerhead, intron, hairpin, etc.), proteins (cytokines, growth factors, cytokinin antagonists, etc), antiviral agents (proteases, nucleotides, etc.), chemokines, chemokine antagonists (.e.g, antagonists, including antibodies to, e.g., RANTES, MlP-la, MTP-lb).
- the suspected agent can be added to the mixture as described above and the number of cells captured in the presence or absence of the agent tested or measured.
- the cells can be pretreated with the agent, e.g., to identify agents which interfere with viral infection after the virus has entered the cell.
- the agent can be added to the mixture at the same time as the virus, e.g., to identify agents which interfere with viral attachment to the cell or which disable the virus before attachment.
- Various samples can be used in the present invention, including, any material suspected of containing cells or agents which interfere with viral infection or virus, itself, such as blood, lymph, tissues, organs, in vitro cell culture, urine, saliva, sweat, water samples (e.g., for testing drinking water quality), cell culture media, FBS, serum, feces, food, saline solutions, etc.
- Such material can be derived from any source or species, including invertebrates, vertebrates, bacteria, mammals, such as humans, apes, monkeys, etc., mollusks, insecta, etc.
- a related aspect of the present invention involves isolation of viruses from samples, e.g., HIV from plasma.
- HIV can be isolated from plasma by coupling 2 nm magnetic microbeads with anti-gp4 and/or anti-gp 120.
- the technique will enrich the virus concentration by immunomagnetic separation with no loss of virus through centrifugation and permit efficient separation from plasma inhibitors of PCR.
- the same methods described above for cells can therefor can be used for viral isolation.
- magnetic microbeads e.g., from about 0.5-10 nm, preferably 1-5 nm can be used.
- Flow cytometry can be accomplished conventionally.
- the coated cells are eluted from the magnetic separation apparatus. See, e.g., USP 5,411,863. Such cells can then be subjected to flow cytometry according to any method. See, e.g., Hiebert, R.D., "Electronics and Signal Processing", Flow Cytometry and Sorting, Second Ed., Wiley-Liss Inc., pp. 127-155, 1990; M.
- Test Kit Fig. 1 shows the Cartridge Antigen Test (CAT), comprising a cartridge 16 and a clear rectangular piece of plexiglas, 3/8" thick, 2 wide, and 3" long.
- the well 14 a 1/4" deep central hemispherical depression in the middle of the cartridge 16, holds the micro-baggy containing the mixture of reagents 12 and three micro-lances 10.
- the well 14 is covered by a clear mylar strip 18 and adhesive fastener 20.
- a bar code strip 22 is near the bottom of the cartridge 16.
- Fig. 2 shows that the well 14 is clear and transparent on the sides, top and bottom, allowing light to pass through the reagent/blood mixture.
- Fig. 3 shows one of the three micro-lanes 10 which protrude from the bottom of the center of the depression or well 14. Sitting just above the three micro-lances 10 is a micro-baggy containing the mixture of reagents 12.
- Fig. 4A shows how a test subject holds his/her hand above the well 14 of the cartridge 16.
- Fig 4B illustrates how the pressing of the thumb on the micro-baggy containing the mixture of reagents 12 above the three micro-lances 10 will cause the test subject to bleed, the blood to be mixed with the reagents.
- Fig. 4C shows how the cartridge 16 is sealed after collection with the clear mylar strip 18 by lowering the mylar strip 18 into contact with the adhesive strip 20.
- Fig 5A is a side view of the well 14 before the test subject bursts the micro-baggy containing the mixture of reagents 12.
- the well 14 contains two reagents needed for the magnetic separation and fluorescent identification: antibodies coupled to paramagnetic microspheres 30 and antibodies coupled with a fluorochrome 32.
- Fig 5B is a side view of the well 14 covered with the clear mylar strip 18, with the wholl blood sample and reagents prior to incubation.
- Fig 5C is a side view of the well 14 covered with the clear mylar strip 18, after mixing the whole blood sample with the reagents.
- Incubation 40 is applied to the cartridge 16 and the uninfected peripheral blood lymphocytes 24 remain unaffected by the reagents.
- the incubation 40 produces antibodies noncompetively bound to infected peripheral blood lymphocytes 34.
- Fig. 5D shows the well 14, being exposed to a strong magnetic gradient 42.
- the magnetic field caused the migration to the inner surface of the well 14 of all the antibodies noncompetively bound to infected peripheral blood lymphocytes 34 to the point of concentration of the magnetic gradient 42, thus separating the antibodies noncompetively bound to infected peripheral blood lymphocytes 34 from the uninfected peripheral blood lymphocytes 24.
- the magnetic separation takes approximately 20 seconds.
- Fig. 5E shows a side view of the well 14 after the magnetic separation has occurred.
- the predetermined point of maximum magnetic concentration is illuminated by a suitable focused light source 44, for example, at 488 nm wavelength, for FICT, causing all antibodies noncompetively bound to infected peripheral blood lymphocytes 34 now aggregated at the predetermined point to glow 48 at between 520-540 nm fluorescent light.
- the reaction can then be viewed through a microscope or lens of an imaging system.
- Fig 6 A shows a stop surface view of the cartridge 16.
- Fig 6B shows the antibodies noncompetively bound to infected blood lymphocytes 34 being separated from the uninfected peripheral blood lymphocytes 24 by the magnetic field to the concentration pont of the magnetic gradient 24.
- Fig. 6C is a side view of the cartridge 16 and shows how the focused light source 44 is directed through the bottom of the well 14 and the lens 46 placed above the well 14 to view the glow 48 from the reaction.
- a test subject presses his/her thumb or finger down onto the micro-baggy containing the mixture of reagents 12 on the CAT.
- the micro-baggy containing the mixture of reagents 12 bursts.
- the three micro-lances 10 puncture the thumb or finger causing the individual to bleed.
- the clear mylar strip 18 is pulled down and fastened by adhesive fastener 20, sealing the well 14 containing the blood and the reagents.
- the first reagent must comprise anti-bodies coupled to paramagnetic microspheres 30 and the second must consist of anti-bodies coupled with a Fluorochrome 32. Both reagents will bind themselves to the infected or target antigen-coated cells during the incubation 40.
- the mixture in the sealed cartridge 16 is incubated for 3 to 5 minutes at 37 degrees Centigrade.
- the cartridge 16 is then moved to a viewing platform.
- a strong magnetic gradient 42 is applied to the side of the well 14. The magnetic field causes the target antibodies, noncompetively bound to infected peripheral blood lymphocytes
- a forced light source 44 measuring 488 nm is passed through well 14 and the blood and reagent mixture.
- the focused light source 44 causes antibodies noncompetively bound to infected peripheral blood lymphocytes 34 to glow 48 at the specific emmision frequency determined by the specific fluorochrome.
- the reaction can be viewed through a lens 46 or predetermined coordinates of the magnetic gradient 42 with the highest concentration at the inner surface of the well 14 where the antibodies noncompetively bound to infected peripheral blood lymphocytes 34 will be located. If there is no glow then the result is negative, and if there is a glow 48 the result is positive.
- the test subject is identified by the bar code strip 22 attached to the cartridge 16. Accordingly, it can be seen that the invention simplifies the procedures of blood collection, reagent mixing, patient tracking and test reading by unifying all steps into one functional unit.
- the positioning of the micro-baggy containing the mixture of reagents 12 above the three micro-lanes 10 allows for blood collection and mixing with the reagents in one step.
- the clear mylar strip 18 is used to cover the exposed well 14 and the cartridge 16 is incubated 40 at 37 degrees Centigrade.
- the invention works with two reagents.
- the first reagent consists of antibodies coupled to paramagnetic microspheres 30 so that the infected peripheral blood lymphocytes 26 can be separated from uninfected peripheral blood lymphocytes 24 by applying a magnetic gradient 42.
- the magnetic field generated by the magnetic gradient 42 will cause the antibodies coupled to paramagnetic microspheres 30 attached to the infected peripheral blood lymphocytes 26 to be drawn to a predetermined location of the interior wall of the well 14.
- the second reagent consists of antibodies coupled with a fluorochrome 32 so that the infected peripheral blood lymphocytes 26 can be identified if present by applying a focused light source 44 on the well 14 causing the infected peripheral blood lymphocytes 26 to glow at the specific emission frequency determined by the specific fluorochrome.
- the well 14, covered with a clear mylar strip 18, allows the cartridge 16 to move around and allows the test reaction to be viewed through a lens 46.
- HIV-1 Isolation System For the numerous instances when it is desirable to separate HIV-1 infected cells from a mixture of uninfected cells, an HIV-1 -infected cell isolation system utilizing imunomagnetic separation can be used. The mixture of infected and uninfected cells is washed, centrifuged and resuspended in PBS . A polyclonal anti-GP 120-FITC is introduced into the resuspended cells and incubated for 10 minutes. The cells are separated by centrifugation and washed. Anti-FITC microbeads are used to separate the fluorescently labeled HIV-1 -infected cells using positive selection columns. Flow cytometry is used to quantitate the separated HIV-1 -infected cells.
- This same isolation system can be used with other virally-infected cells, such as SIV or HTLV.
- a neutralization assay is used to determine the quantity of neutralizing antibody activity in sera.
- a positive control is established by inoculating receptive CM 174 cells (or another receptive viral receptive) in suspension with a mixture of cultured laboratory isolates of HIV-1 (MN and IIIB strains). After 7 days of incubation, the cells are separated by centrifugation, washed and resuspended in PBS.
- Anti-GP 120-FITC is introduced into the resuspended cells and incubated for 10 minutes. The cells are separated by centrifugation and washed.
- Anti-FITC Microbeads are used to separate the fluorescently labeled HIV-1 infected cells using positive selection columns. The HIV-infected cells are then quantified using standard flow cytometry.
- the procedure for determining neutralizing activity of sera is performed by adding serially diluted sera specimens to the mixture of virus and CM174 cells and incubating for the same time as used for the positive control.
- Anti-GP 120-FITC and Anti-FITC Microbeads are used in the same way as in the positive control to separate and enumerate the HIV-1 -infected cells.
- the neutralizing activity of each serum specimen is determined by the difference from the positive control in the quantity of HIV- infected cells isolated after treatment and incubation of cells and virus with neutralizing sera.
- This same assay can be performed with other virallly-infected cells, such as SIV or HTLV-1.
- an HIV-1 drug screening assay is used to identify new anti-HIV drug candidates' ability to block HIV-1 replication in vitro.
- a positive control is established by inoculating BTI's receptive CM174 cells in suspension with mixture of cultured laboratory isolates of HIV-1 (MN and IIIB strains). After 7 days of incubation, the cells are separated by centrifugation, washed and resuspended in PBS.
- Anti-GP 120-FITC is introduced into the resuspended cells and incubated for 10 minutes. The cells are separated by centrifugation and washed. Anti-FITC Microbeads are used to separate the fluorescently labeled HIV-1 -infected cells using positive selection columns. The HIV-infected cells are then quantified using standard flow cytometry.
- the procedure for determining antiviral activity of new drug candidates is performed by adding serially diluted specimens of the candidate to the mixture of virus and CM 174 cells and incubating for the same time as used for the positive control.
- Anti-GP 120-FITC and Anti FITC Microbeads are used in the same way as in the positive control to separate and enumerate the HIV-1 -infected cells.
- the antiviral activity of each candidate is determined by noting the dose related differences from the positive control in the quantity of HIV-infected cells isolated after treatment and incubation of cells and virus with the drug candidate.
- This same screening assay can be performed using other virally-infected cells, such as SIV or HTLV
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP51858298A JP2001503859A (en) | 1996-10-15 | 1997-10-15 | HIV-infected cell detection reagent system and kit therefor |
APAP/P/1999/001515A AP9901515A0 (en) | 1996-10-15 | 1997-10-15 | Reagent system and kit or detecting HIV infected cells. |
EP97910976A EP0933989A1 (en) | 1996-10-15 | 1997-10-15 | Reagent system and kit for detecting hiv infected cells |
AU48224/97A AU743937B2 (en) | 1996-10-15 | 1997-10-15 | Reagent system and kit for detecting HIV infected cells |
US09/296,534 US20010039007A1 (en) | 1996-10-15 | 1999-04-22 | Methods and compositions for determining latent viral load |
US09/893,604 US7521176B2 (en) | 1996-10-15 | 2001-06-29 | Methods for characterizing the viral infectivity status of a host |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/732,782 | 1996-10-15 | ||
US08/732,782 US5817458A (en) | 1996-10-15 | 1996-10-15 | Reagent system for detecting HIV-infected peripheral blood lymphocytes in whole blood |
US08/732,784 | 1996-10-15 | ||
US08/732,784 US5714390A (en) | 1996-10-15 | 1996-10-15 | Cartridge test system for the collection and testing of blood in a single step |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/732,782 Continuation-In-Part US5817458A (en) | 1996-10-15 | 1996-10-15 | Reagent system for detecting HIV-infected peripheral blood lymphocytes in whole blood |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09139663 A-371-Of-International | 1997-10-15 | ||
US09/139,633 A-371-Of-International US6127490A (en) | 1996-10-15 | 1998-08-25 | Varnish compositions, methods of making and components made therefrom |
US09/296,534 Continuation US20010039007A1 (en) | 1996-10-15 | 1999-04-22 | Methods and compositions for determining latent viral load |
US09/299,625 Continuation US6461809B1 (en) | 1996-10-15 | 1999-04-27 | Methods of improving infectivity of cells for viruses |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998016101A1 true WO1998016101A1 (en) | 1998-04-23 |
Family
ID=27112456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/018649 WO1998016101A1 (en) | 1996-10-15 | 1997-10-15 | Reagent system and kit for detecting hiv infected cells |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0933989A1 (en) |
JP (1) | JP2001503859A (en) |
AP (1) | AP9901515A0 (en) |
AU (1) | AU743937B2 (en) |
WO (1) | WO1998016101A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000065355A1 (en) * | 1999-04-22 | 2000-11-02 | Bio-Tech Imaging, Inc. | Methods and compositions for determining latent viral load |
WO2002003064A1 (en) * | 2000-06-30 | 2002-01-10 | Bio-Tech Imaging, Inc. | Methods for characterizing the viral infectivity status of a host |
FR2832507A1 (en) * | 2001-11-20 | 2003-05-23 | Stago Diagnostica | Detecting and quantifying analytes, useful e.g. for antibodies or antigens, based on formation of chains of functionalized, colloidal magnetic particles |
EP1771736A1 (en) * | 2004-07-20 | 2007-04-11 | Cgk Co., Ltd. | System for detecting molecular interactions |
CN107290534A (en) * | 2017-07-12 | 2017-10-24 | 华讯方舟科技有限公司 | A kind of blood cell capture chip and method |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004031209A2 (en) * | 2002-10-01 | 2004-04-15 | Functional Genetics, Inc. | Anti-tsg101 antibodies and their uses for treatment of viral infections |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4659678A (en) * | 1982-09-29 | 1987-04-21 | Serono Diagnostics Limited | Immunoassay of antigens |
US4777145A (en) * | 1984-10-12 | 1988-10-11 | Labsystems Oy | Immunological assay method using magnetic particles |
US5054499A (en) * | 1989-03-27 | 1991-10-08 | Swierczek Remi D | Disposable skin perforator and blood testing device |
US5231993A (en) * | 1991-11-20 | 1993-08-03 | Habley Medical Technology Corporation | Blood sampler and component tester with guide member |
US5541072A (en) * | 1994-04-18 | 1996-07-30 | Immunivest Corporation | Method for magnetic separation featuring magnetic particles in a multi-phase system |
US5543289A (en) * | 1988-12-28 | 1996-08-06 | Miltenyi; Stefan | Methods and materials for improved high gradient magnetic separation of biological materials |
-
1997
- 1997-10-15 AU AU48224/97A patent/AU743937B2/en not_active Ceased
- 1997-10-15 JP JP51858298A patent/JP2001503859A/en active Pending
- 1997-10-15 WO PCT/US1997/018649 patent/WO1998016101A1/en not_active Application Discontinuation
- 1997-10-15 AP APAP/P/1999/001515A patent/AP9901515A0/en unknown
- 1997-10-15 EP EP97910976A patent/EP0933989A1/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4659678A (en) * | 1982-09-29 | 1987-04-21 | Serono Diagnostics Limited | Immunoassay of antigens |
US4777145A (en) * | 1984-10-12 | 1988-10-11 | Labsystems Oy | Immunological assay method using magnetic particles |
US5543289A (en) * | 1988-12-28 | 1996-08-06 | Miltenyi; Stefan | Methods and materials for improved high gradient magnetic separation of biological materials |
US5054499A (en) * | 1989-03-27 | 1991-10-08 | Swierczek Remi D | Disposable skin perforator and blood testing device |
US5201324A (en) * | 1989-03-27 | 1993-04-13 | Remi Swierczek | Disposable skin perforator and blood testing device |
US5231993A (en) * | 1991-11-20 | 1993-08-03 | Habley Medical Technology Corporation | Blood sampler and component tester with guide member |
US5541072A (en) * | 1994-04-18 | 1996-07-30 | Immunivest Corporation | Method for magnetic separation featuring magnetic particles in a multi-phase system |
Non-Patent Citations (4)
Title |
---|
CLIN. CHEM., 1987, Vol. 33, No. 9, BIRKMEYER et al., "Application of Novel Chromium Dioxide Magnetic Particles to Immunassay Development", pages 1543-1547. * |
J. IMMUNOL. METH., 1991, Vol. 137, LUK et al., "Rapid and Sensitive Detection of Salmonella (O:6,7) by Immunomagnetic Monoclonal Antibody-Based Assays", pages 1-8. * |
SCIENCE, 04 May 1984, Vol. 224, READ et al., "Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS", pages 500-503. * |
SCIENCE, 24 August 1984, Vol. 225, LEVY et al., "Isolation of Lymphocytopathic Retroviruses from San Francisco Patients with AIDS", pages 840-842. * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000065355A1 (en) * | 1999-04-22 | 2000-11-02 | Bio-Tech Imaging, Inc. | Methods and compositions for determining latent viral load |
WO2002003064A1 (en) * | 2000-06-30 | 2002-01-10 | Bio-Tech Imaging, Inc. | Methods for characterizing the viral infectivity status of a host |
FR2832507A1 (en) * | 2001-11-20 | 2003-05-23 | Stago Diagnostica | Detecting and quantifying analytes, useful e.g. for antibodies or antigens, based on formation of chains of functionalized, colloidal magnetic particles |
WO2003044532A1 (en) * | 2001-11-20 | 2003-05-30 | Diagnostica Stago | Method for detecting analyte(s) using magnetic colloidal particles |
US7332353B2 (en) | 2001-11-20 | 2008-02-19 | Diagnostica Stago | Method for detecting analyte(s) using magnetic colloidal particles |
EP1771736A1 (en) * | 2004-07-20 | 2007-04-11 | Cgk Co., Ltd. | System for detecting molecular interactions |
EP1771736A4 (en) * | 2004-07-20 | 2008-08-13 | Cgk Co Ltd | System for detecting molecular interactions |
CN107290534A (en) * | 2017-07-12 | 2017-10-24 | 华讯方舟科技有限公司 | A kind of blood cell capture chip and method |
Also Published As
Publication number | Publication date |
---|---|
AP9901515A0 (en) | 1999-06-30 |
JP2001503859A (en) | 2001-03-21 |
AU743937B2 (en) | 2002-02-07 |
AU4822497A (en) | 1998-05-11 |
EP0933989A1 (en) | 1999-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5817458A (en) | Reagent system for detecting HIV-infected peripheral blood lymphocytes in whole blood | |
EP1590669B1 (en) | A microchip-based system for hiv diagnostics | |
RU2251111C2 (en) | Methods for detecting both components of binding pair | |
IL109008A (en) | Antigen density-independent immunoassay for determination of cells | |
US5637453A (en) | Whole blood method and kit for the detection of antibodies against human immunodeficiency virus (HIV) in HIV-seronegative individuals | |
US20010008760A1 (en) | Reagent system and kit for detecting hiv infected cells | |
EP0289339A1 (en) | Detection of antibodies to human immunodeficiency virus | |
US20090104650A1 (en) | Infectious diseases testing of menstrual fluid, endometrial/menstrual cells, amniotic fluid, umbilical cord blood or other samples | |
AU743937B2 (en) | Reagent system and kit for detecting HIV infected cells | |
WO2009084369A1 (en) | Reagent for detecting hiv-1 antigen and detection method | |
Mvere et al. | Rapid and simple hepatitis assays: encouraging results from a blood donor population in Zimbabwe. | |
HUE030824T2 (en) | Method for diagnosing and differentiating hiv-2 infections | |
Hashida et al. | Immune complex transfer enzyme immunoassay that is more sensitive and specific than Western blotting for detection of antibody immunoglobulin G to human immunodeficiency virus type 1 in serum with recombinant pol and gag proteins as antigens | |
US6352826B1 (en) | Method and kit for the detection of retroviral specific antibodies in seronegative individuals | |
CA2578313A1 (en) | Highly accurate rapid parallel immunoassay device | |
AU2811201A (en) | Reagent system and kit for detecting HIV infected cells | |
JP3889045B2 (en) | Peptides for detecting HIV | |
JP2001305139A (en) | Specific bond body | |
AU2008299884A1 (en) | Infectious disease testing of menstrual fluid, endometrial /menstrual cells, amniotic fluid, umbilical cord blood or other samples | |
CN113624977A (en) | Diagnostic method for SARS-CoV-2 infection | |
Burgess-Cassler et al. | A field test for the detection of antibodies to human immunodeficiency virus types 1 and 2 in serum or plasma | |
RU2686490C1 (en) | Kit for multiplex immunochemical analysis of antibodies and antigens in blood preparations | |
Mualif | RAPID DETECTION KIT FOR ANTIBODY-ANTIGEN RECOGNIZATION FOR HUMAN IMMUNODEFICIENCY VIRUS | |
JPH08511104A (en) | Immunoassay | |
CN117347624A (en) | Fluorescence quenching immunochromatography test strip and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09139663 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page |
Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 518582 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997910976 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997910976 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997910976 Country of ref document: EP |